Naproxen Tablet, Delayed Release
NDC 90096-161
Product Information
Naproxen is a NDA AUTHORIZED GENERIC-approved product labeled by Zameer Pharmaceuticals Llc. See also Warning section. It is supplied as a white tablet, delayed release for oral administration. This product entry covers the primary NDC 90096-161 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
NPR;EC;500
Code Structure Chart
Product Details
What is NDC 90096-161?
What are the uses of this product?
What are Active Ingredients of this product?
- NAPROXEN 500 mg/1 - An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NAPROXEN (UNII: 57Y76R9ATQ)
- NAPROXEN (UNII: 57Y76R9ATQ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- POVIDONE (UNII: FZ989GH94E)
- TALC (UNII: 7SEV7J4R1U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- TRIETHYL CITRATE (UNII: 8Z96QXD6UM)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) (UNII: 74G4R6TH13)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 311915 - naproxen 500 MG Delayed Release Oral Tablet
- RxCUI: 311915 - naproxen (as naproxen sodium) 500 MG Delayed Release Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.